AbbVie Provides Update Regarding RINVOQ® (upadacitinib) in Psoriatic Arthritis and Ankylosing Spondylitis in the U.S. ...Middle East

NORTH CHICAGO, Ill., June 25, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has informed the company that the FDA will not meet the Prescription Drug User Fee Act (PDUFA) action dates for the supplemental New Drug Applications...

Hence then, the article about abbvie provides update regarding rinvoq upadacitinib in psoriatic arthritis and ankylosing spondylitis in the u s was published today ( Friday 25/06/2021 - 03:45 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( AbbVie Provides Update Regarding RINVOQ® (upadacitinib) in Psoriatic Arthritis and Ankylosing Spondylitis in the U.S. )

Also on site :

• Hundreds of flights delayed at O'Hare after pipe burst at air traffic control tower
• Two dead in floods & torrential rains sweeping through Tunisia
• ‘High School Musical’ Turns 20 Today! See Where the Cast Is Now